Drug delivery particle and method for producing the same
AssigneeNational Center of Neurology and Psychiatry
InventorsTakashi Okada, Shin'ichi Takeda, Hiromi Kinoh
Life of this patent
Estimating the term…
Abstract
An object of the present invention is to develop and provide a method for conveniently introducing a nucleic acid, a peptide, and/or a low-molecular-weight compound into an empty capsid with viral early infection activities kept. The present invention provides a method for producing a drug delivery particle, comprising the steps of: mixing an empty capsid or an empty particle with a drug including a nucleic acid, a peptide, and/or a low-molecular-weight compound in a solution comprising 0.1 to 20% of a surfactant; and keeping the obtained mixed solution at −5 to 50° C. to introduce the drug into the empty capsid or the empty particle.
Claims4
A method for producing a HEK293 cell line having the enhanced ability to produce adeno-associated virus, comprising a step of simultaneously introducing to a HEK293 cell already endogenously expressing E1A and E1B19k genes:
- an additional E1A gene,
- an additional E1B19k gene,
- an E2A gene,
- an E4orf6 gene, and
- a VA RNA-encoding gene derived from adenovirus,
- thereby producing the HEK293 cell line having the enhanced ability to produce adeno-associated virus,
- wherein the enhancement is at least 1.6 fold as compared to the HEK293 cell line without introducing the E1A gene and the E1B19k gene.
A method for producing a HEK293EB cell having the enhanced ability to produce adeno-associated virus, comprising:
- a first step of introducing to a HEK293 cell already endogenously expressing E1A and E1B19k genes a plasmid expressing an E1 coding region comprising an additional E1A gene and an additional E1B19k gene, and Bcl-xL gene, thereby producing a HEK293EB cell stably expressing the E1 coding region and Bcl-xL gene;
- a second step of isolating the HEK293EB cell;
- a third step of introducing to the HEK293EB cell an E2A gene, an E4orf6 gene, and a VA RNA-encoding gene derived from adenovirus,
- thereby producing the HEK293EB cell having the enhanced ability to produce adeno-associated virus, wherein the enhancement is at least 1.6 fold as compared to the HEK293 cell without introducing the additional E1A gene and the E1B19k gene.
Dependencies are inferred from the claim text.